Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. has focused on the biopharmaceutical field for 15 years, with a valuation of 3.22 billion yuan after raising a total of 1.04 billion yuan through seven rounds of financing, and is now attempting to go public on the Hong Kong Stock Exchange to address funding bottlenecks in research and commercialization [1][4]. Group 1: Company Overview - Binhui Biotechnology has developed a differentiated pipeline that includes oncolytic viruses, nucleic acid therapies, and protein biopharmaceuticals, with BS001 and BS006 as core products [2][3]. - BS001 is a novel oncolytic virus candidate based on HSV-2, currently in Phase III clinical trials, and aims to treat various solid tumors [2][3]. - BS006, another oncolytic virus, targets difficult-to-treat solid tumors and received clinical trial approval in August 2025 [3]. Group 2: Financial Performance - Despite a promising pipeline, Binhui Biotechnology has not yet commercialized any products, resulting in continuous losses and cash flow pressures [7][8]. - The company reported revenues of 981,000 yuan in 2023, with projections of 1.725 million yuan in 2024, but a significant drop to 140,000 yuan in the first half of 2025, reflecting a 44% year-on-year decline [7]. - Cumulative losses reached 267 million yuan over two and a half years, with net losses of 110 million yuan in 2023 and 113 million yuan in 2024 [7]. Group 3: Investment and Market Position - The company has attracted significant investment, with early investors experiencing capital losses as some chose to exit at lower prices than their initial investments [6]. - Binhui Biotechnology's IPO plans have faced multiple adjustments, reflecting challenges in market positioning and strategic direction [8]. - The upcoming IPO aims to raise funds primarily for the global Phase III trial of BS001 and to enhance research and commercialization capabilities [8].

Core Viewpoint - The company Binhui Biotechnology is seeking to go public on the Hong Kong Stock Exchange, despite having no approved products, no sales revenue, and continuous losses, due to its HSV-2 oncolytic virus candidate drug entering Phase III clinical trials, attracting significant capital interest [1][3]. Company Overview - Binhui Biotechnology focuses on developing oncolytic virus therapies, specifically using the HSV-2 virus, which is believed to have better safety and greater gene-carrying capacity compared to the more common HSV-1 [5]. - The founder, Liu Binlei, has over 30 years of experience in tumor immunology and was involved in the development of the first FDA-approved oncolytic virus drug, IMLYGIC [4]. Market Potential - The global oncolytic virus market is projected to reach approximately $871 million in 2024, with the Chinese market estimated at around 45.3 million RMB. By 2030, the global market could grow to $7.5 billion, and the Chinese market may expand to 9.2 billion RMB [5]. Product Pipeline - Binhui has five products in various stages of development, with BS001 being the first HSV-2 oncolytic virus candidate to enter Phase III trials globally, and BS006 being the first bispecific antibody oncolytic virus currently in Phase I trials in the U.S. [7][8]. - BS001 has shown promising clinical data, with one-year and two-year overall survival rates of 91.0% and 72.0%, respectively, in melanoma patients [7]. Financial Performance - The company has reported cumulative losses exceeding 520 million RMB, with revenues from research services and reagent sales being minimal, indicating a "high investment, zero revenue" situation [9]. - As of June 30, 2025, Binhui had cash and equivalents of 166 million RMB, sufficient to cover operational needs for at least 12 months [9]. Investment and Financing - Binhui has completed seven rounds of financing, raising a total of 1.04 billion RMB, with significant early investments from local capital in Wuhan [10]. - The company's valuation has fluctuated significantly, with early investors experiencing both gains and losses in their share transfers [11]. Listing Journey - Binhui's path to listing has been complicated, having explored various markets including the Hong Kong Stock Exchange, STAR Market, and Beijing Stock Exchange before finally submitting its application to the Hong Kong Stock Exchange in September 2025 [12].

Core Viewpoint - The article discusses the innovative approach of using oncolytic viruses for cancer treatment, highlighting the case of Wuhan Binhui Biotechnology Co., Ltd. (Binhui Bio) as it applies for an IPO on the Hong Kong Stock Exchange despite having no approved products, no sales revenue, and continuous losses. The company is gaining attention due to its HSV-2 oncolytic virus candidate drug, which is the first to enter Phase III clinical trials globally [1][2]. Company Overview - Binhui Bio aims to become the first publicly listed company in China focused entirely on oncolytic virus therapies. The founder, Liu Binlei, has over 30 years of experience in tumor immunology and was involved in the development of the first FDA-approved oncolytic virus drug, IMLYGIC [2]. - The company has chosen a differentiated path by focusing on the HSV-2 virus platform, which is believed to have greater safety and gene-carrying capacity compared to the more common HSV-1 [2]. Market Potential - The global oncolytic virus market is projected to reach approximately $871 million in 2024, with the Chinese market estimated at around 45.3 million RMB. By 2030, the global market could grow to $7.5 billion, and the Chinese market may expand to 9.2 billion RMB [3]. - Oncolytic viruses are expected to have fewer side effects compared to traditional therapies and can synergize with existing treatments, potentially leading to enhanced efficacy [3]. Product Pipeline - Binhui Bio has five products in various stages of development, with BS001 and BS006 being the core products. BS001 is the first HSV-2 oncolytic virus candidate to enter Phase III trials and has received orphan drug designation from the FDA for treating advanced melanoma [4][5]. - Clinical data for BS001 shows promising survival rates, with one-year and two-year overall survival rates of 91.0% and 72.0%, respectively. The drug has also demonstrated a favorable safety profile [5]. Financial Overview - Binhui Bio has accumulated losses exceeding 520 million RMB, primarily due to R&D expenditures for BS001 and BS006. The company reported minimal revenue from R&D services and reagent sales, with drug sales generating no income [6][8]. - The company has raised a total of 1.04 billion RMB through seven rounds of financing, indicating strong investor interest despite its financial challenges [8]. IPO Journey - Binhui Bio's path to IPO has been complex, having considered multiple stock exchanges before finally applying to the Hong Kong Stock Exchange in September 2023. The company previously explored listings on the STAR Market and the Beijing Stock Exchange [11].

Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. has submitted its IPO application to the Hong Kong Stock Exchange, focusing on cancer immunotherapy with a pipeline that includes oncolytic viruses, nucleic acid therapies, and protein biologics [1][3] Company Overview - Founded in 2010, Binhui Biotechnology has completed 13 rounds of financing, raising over 1.5 billion yuan, with a post-money valuation of 3.22 billion yuan as of June 30, 2025 [1] - The company has attracted investments from notable firms such as Yangtze River Pharmaceutical Group and China International Capital Corporation [1] Product Pipeline - The core product BS001 is the world's first oncolytic virus candidate using a type II herpes simplex virus (HSV-2) that has entered Phase III trials, targeting melanoma and expanding to colorectal cancer and glioblastoma [3] - BS006, another significant product, is the first dual-antibody oncolytic virus to enter clinical stages, focusing on difficult-to-treat solid tumors [3] - Additional early-stage pipelines include nucleic acid therapies BR003, BS051, and protein biologics BR016 [3] Financial Performance - The company reported revenues of 981,000 yuan in 2023, 1.725 million yuan in 2024, and 140,000 yuan in the first half of 2025, with a 44% year-on-year decline in the first half of 2025 [3] - Net losses were 110 million yuan in 2023, 113 million yuan in 2024, and 44.215 million yuan in the first half of 2025, totaling over 270 million yuan in losses over two and a half years [3] - As of June 30, 2025, cash and cash equivalents stood at 166 million yuan, with a projected net loss of 113 million yuan in 2024, indicating a runway of approximately 1.5 years [3] Market Outlook - The oncolytic virus market in China is projected to grow from 2.7 billion yuan in 2023 to 3.5 billion yuan in 2024, representing a growth rate of 29.6%, but with a low penetration rate of about 12.4% [4] - Patient awareness of oncolytic virus therapies is limited, and most products are not included in medical insurance, leading to high treatment costs exceeding 100,000 yuan per course [4] Competitive Landscape - Binhui Biotechnology's BS001 faces challenges similar to those of Amgen's T-VEC, which has limited indications and complex administration methods that restrict its clinical application [5] - The company must build a robust sales network and train medical staff to effectively promote its products, as its current sales and marketing team is underrepresented [6] - Established pharmaceutical companies are also investing in oncolytic virus therapies, creating a competitive environment for Binhui Biotechnology [6]

Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. is gaining significant attention from capital markets due to its innovative cancer immunotherapy, specifically its HSV-2 oncolytic virus candidate drug, despite having no approved products, no sales revenue, and consecutive years of losses [5][6]. Company Overview - Founded in 2010, Binhui Biotech focuses on the discovery, development, and commercialization of innovative cancer immunotherapies, with a clear technical path centered on the development of an HSV-2 vector platform [9][10]. - The company has established a diverse pipeline that includes oncolytic viruses, nucleic acid therapies, and protein biologics, with several products at different stages of development [10][11]. Financial Performance - The company reported revenues of 980,000 yuan, 1.725 million yuan, and 140,000 yuan for 2023, 2024, and the first half of 2025, respectively, primarily from R&D services and not from drug sales [14][15]. - Net losses for the same periods were 110 million yuan, 113 million yuan, and 44.22 million yuan, with total losses exceeding 270 million yuan over two and a half years, driven by high R&D expenditures [16]. - As of June 30, 2025, the company had cash and cash equivalents of 166 million yuan, with operating cash flow improving from -127 million yuan in 2023 to -79.13 million yuan [17]. Investment and Valuation - Binhui Biotech has completed seven rounds of financing, raising over 1 billion yuan, with a post-investment valuation of 3.22 billion yuan [18][20]. - The company has attracted investments from notable firms, including Lepu Medical, CICC Capital, and others, indicating strong market interest [20]. Market Potential - The global oncolytic virus therapy market is rapidly growing, with an expected compound annual growth rate (CAGR) of 26.9% from 2024 to 2032 [8]. - Currently, only four oncolytic virus drugs have regulatory approval, and Binhui Biotech is among the fastest in development, with its core product BS001 being the first HSV-2 oncolytic virus candidate to enter Phase III clinical trials [10][21]. Competitive Advantage - Binhui Biotech holds a unique position in the market as the only company in China with a production license for oncolytic virus drugs, ensuring its capability for large-scale production and commercialization [21].

Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, marking a new development phase and strengthening its global strategic layout [1] Company Overview - Binhui Biotechnology, established in 2010, focuses on the research and commercialization of oncolytic virus therapies, with a strong emphasis on innovative cancer immunotherapy [1] - The founder, Dr. Liu Binlei, has over 30 years of expertise in tumor immunology and oncolytic virology, being a core member of the original development team for the FDA-approved oncolytic virus drug IMLYGIC (T-VEC) [1] - The company has completed 13 rounds of financing, raising over 1.5 billion RMB, with a valuation of 3.22 billion RMB post-2023 financing, reflecting strong market recognition of its technology and business prospects [1] Financial Performance - Binhui Biotechnology is currently in a strategic investment phase, with revenues of 981,000 RMB, 1.725 million RMB, 250,000 RMB, and 140,000 RMB for the fiscal years 2023, 2024, and the six months ending June 30, 2024, and 2025, respectively [1][2] - The company reported losses of approximately 110 million RMB, 113 million RMB, 43.748 million RMB, and 44.215 million RMB for the same periods [1][2] - R&D expenses reached 107 million RMB in 2023, accounting for 92% of total expenditures, with a continued high percentage expected in 2024 [2] Product Pipeline - Binhui Biotechnology has established a diverse pipeline, including oncolytic viruses, nucleic acid therapies, and protein biologics, with five products at various development stages, many of which have global first-in-class potential [2][6] - The core product, BS001 (OH2 injection), is the first oncolytic virus candidate to reach clinical stage III globally, showing potential as a first-in-class new drug [4] - BS001 has demonstrated good safety and preliminary efficacy in early clinical trials, with an objective response rate of 34.48% in advanced melanoma patients and 42.1% in patients resistant to PD-1 therapy [5] Competitive Landscape - The oncolytic virus therapy sector is gaining momentum, with significant interest from major pharmaceutical companies following the approval of T-VEC in 2015 [7] - Despite challenges in the market, including effective delivery and regulatory hurdles, the sector remains a vast blue ocean with numerous ongoing clinical trials, particularly from Chinese innovative drug companies [8] Future Outlook - With the maturation of oncolytic virus technology and rapid R&D progress, Binhui Biotechnology is positioned to capture market share in this emerging field, potentially leading to upward momentum in both performance and valuation [10]

Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, marking a new development phase and strengthening its global strategic layout [1] Company Overview - Founded in 2010, Binhui Biotechnology focuses on the research and commercialization of oncolytic virus therapies, with a strong emphasis on innovative cancer immunotherapy [1][2] - The founder, Dr. Liu Binlei, has over 30 years of expertise in tumor immunology and oncolytic virology, being a core member of the original development team for the first FDA-approved oncolytic virus drug, IMLYGIC® (T-VEC) [1] Financial Performance - Binhui Biotechnology has completed 13 rounds of financing, raising over 1.5 billion RMB, with a valuation of 3.22 billion RMB post-2023 financing, reflecting strong market recognition [1] - The company reported revenues of 981,000 RMB, 1.725 million RMB, 250,000 RMB, and 140,000 RMB for the fiscal years 2023, 2024, and the first half of 2024 and 2025, respectively, with losses of approximately 110 million RMB, 113 million RMB, 43.748 million RMB, and 44.215 million RMB during the same periods [1][2] Research and Development - In 2023, R&D expenses reached 107 million RMB, accounting for 92% of total expenditures, with a projected R&D expense ratio of over 85% in 2024 [2] - The company has established a diverse pipeline, including oncolytic viruses, nucleic acid therapies, and protein biologics, with multiple products at various development stages [2][6] Key Products - The core product, BS001 (OH2 injection), is the first oncolytic virus candidate using HSV-2 to enter Phase III clinical trials globally, showing potential as a first-in-class drug [4] - BS001 has demonstrated good safety and preliminary efficacy in early clinical trials, with an objective response rate of 34.48% in advanced melanoma patients and 42.1% in patients resistant to PD-1 therapy [5] - Another key product, BS006, is the first dual-target oncolytic virus to enter clinical trials, utilizing a genetically engineered HSV-2 to express PD-L1/CD3 bispecific T cell engager molecules [5] Industry Context - The oncolytic virus therapy sector is gaining momentum, with significant interest from major pharmaceutical companies following the approval of T-VEC in 2015 [7] - Despite challenges in the field, including effective delivery and regulatory hurdles, the market remains a promising area for growth, with numerous clinical trials ongoing, particularly in China [8][9] - Binhui Biotechnology's unique vertical integration and comprehensive production capabilities position it as a strong competitor in the oncolytic virus market [6][9]

Core Viewpoint - Wuhan's innovative pharmaceutical companies are gaining attention in the capital market, with Wuhan Heyuan Bio (688765.SH) starting its subscription on October 14, and another company, Binhui Bio, seeking a listing on the Hong Kong Stock Exchange [1][2]. Company Overview - Binhui Bio, established in November 2010 and headquartered in Wuhan, focuses on oncolytic virus therapy and aims to discover, develop, and commercialize innovative cancer immunotherapies [2][4]. - The company has undergone seven rounds of investment, totaling approximately 1.04 billion RMB, with a post-investment valuation of about 3.22 billion RMB as of December 2023 [5]. Leadership and Experience - The largest shareholder group, led by Dr. Liu Binlei, holds 26.32% of the company's total shares. Dr. Liu has around 40 years of experience in drug research and development [4][6]. Product Pipeline - Binhui Bio has established a differentiated pipeline focusing on three strategic series: oncolytic viruses, nucleic acid therapies, and protein biologics, with oncolytic viruses as the core [8]. - The core product, BS001, is an oncolytic virus candidate based on HSV-2, currently in Phase III clinical trials, showing a 34.48% objective response rate in advanced melanoma patients [16][17]. Market Potential - The global oncolytic virus market is projected to reach approximately $7.5 billion by 2030, with the Chinese market expected to reach 9.2 billion RMB, driven by increasing clinical applications and investments [12]. Financial Performance - Binhui Bio has not yet commercialized any products, reporting revenues of 0.981 million RMB in 2023 and a cumulative loss of 267 million RMB over two and a half years [25][27]. - The company's R&D expenses are the primary source of losses, with 1.07 billion RMB in 2023 and 1.03 billion RMB in 2024 [27]. Challenges and Opportunities - The oncolytic virus field faces challenges, particularly regarding safety and delivery technologies, but offers potential new treatment options for patients with advanced diseases lacking effective standard therapies [29].

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不 負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Binhui Biopharmaceutical Co., Ltd. 武 漢 濱 會 生 物 科 技 股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求而刊 發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知 悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公司不會 向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香 港公司註冊處處長註冊的本公司招股章程作出投資決定，招股章程的 ...